/PRDS

PRDS Stock - Pardes Biosciences, Inc.

Q: What is the analyst price target for PRDS?

Analyst price target information is not currently available for PRDS.

Q: What is PRDS's market cap?

Market capitalization information is not currently available for PRDS.

Healthcare|Biotechnology|NASDAQ

$2.18+0.93%

+$0.02 (+0.93%) • Aug 30

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.40

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PRDS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.42

52W High$3.67

52W Low$0.75

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021
Revenue	N/A	N/A
Gross Profit	N/A	N/A
Gross Margin	N/A	N/A
Operating Income	$-99,817,000	$38.49M
Net Income	$-93,451,000	$-38,548,000
Net Margin	N/A	N/A
EPS	$-1.61	$-0.68

Company Overview

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.

Visit Website

Earnings History & Surprises

PRDS

Beat Rate

33%

Last 6 quarters

Avg Surprise

+5.7%

EPS vs Estimate

Beats / Misses

2/4

Last 12 quarters

Latest EPS

$0.18

Q3 2023

EPS Surprise History

Q4 21

No data

Q4 21

No data

Q1 22

-70.9%

$-0.38vs$-0.22

Q3 22

+23.1%

$0.48vs$0.39

Q4 22

-18.4%

$0.40vs$0.49

Q1 23

-29.3%

$0.41vs$0.58

Q2 23

-23.1%

$0.30vs$0.39

Q3 23

+152.9%

$0.18vs$-0.34

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q3 2024	Aug 2, 2024	—	—	—	—
Q2 2024	May 3, 2024	—	—	—	—
Q1 2024	Mar 12, 2024	—	—	—	—
Q4 2023	Nov 6, 2023	$-0.27	—	—	—
Q3 2023	Aug 4, 2023	$-0.34	$0.18	+152.9%	✓ BEAT
Q2 2023	May 5, 2023	$0.39	$0.30	-23.1%	✗ MISS
Q1 2023	Mar 14, 2023	$0.58	$0.41	-29.3%	✗ MISS
Q4 2022	Nov 7, 2022	$0.49	$0.40	-18.4%	✗ MISS
Q3 2022	Aug 15, 2022	$0.39	$0.48	+23.1%	✓ BEAT
Q1 2022	Mar 29, 2022	$-0.22	$-0.38	-70.9%	✗ MISS
Q4 2021	Dec 31, 2021	—	$-0.25	—	—
Q4 2021	Nov 12, 2021	—	$-0.20	—	—
Q3 2021	Aug 16, 2021	—	$-0.14	—	—
Q2 2021	May 17, 2021	—	$-0.08	—	—
Q1 2021	Feb 18, 2021	—	—	—	—

Frequently Asked Questions about PRDS

What is PRDS's current stock price?

Pardes Biosciences, Inc. (PRDS) is currently trading at $2.18 per share. The stock has moved +0.93% today.

What is the analyst price target for PRDS?

No analyst price targets are currently available for this stock.

What sector is Pardes Biosciences, Inc. in?

Pardes Biosciences, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is PRDS's market cap?

Pardes Biosciences, Inc. has a market capitalization of $0.14 billion, making it a small-cap company.

Does PRDS pay dividends?

No, Pardes Biosciences, Inc. does not currently pay a dividend to shareholders.